Clinical Trial

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Study acronym: MAVRiC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-03
notable Trial sites expanded: 29 -> 36 locations 2026-07-03
minor Completion pushed: 2029-05-15 -> 2033-03-23 2026-07-03
Trial Details
NCT Number NCT07024706
Lead Sponsor AstraZeneca
Collaborators: AbbVie, Genentech, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Enrollment 80 participants
Start Date 2026-06-04
Primary Completion 2029-05-01 (estimated)
Study Completion 2033-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-06